A New FTC Policy May Alter the Calculus for Some Pharma M&A Deals


William Diaz said a new FTC policy on drug divestitures to secure acquisition approval “might make some [companies] gun-shy about proceeding with an acquisition,” particularly in deals involving generics. Typically, he noted, it is easier to divest a generic medicine being developed, since the amount of investment is less than for a brand-name drug.